JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

4.54 2.48

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.51

Максимум

4.59

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	11M 31M
Предишно отваряне	2.06
Предишно затваряне	4.54

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2.02.2026 г., 23:28 ч. UTC

Пазарно говорене

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2.02.2026 г., 23:23 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2.02.2026 г., 22:57 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2.02.2026 г., 21:51 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.02.2026 г., 21:49 ч. UTC

Печалби

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2.02.2026 г., 21:39 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:36 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2.02.2026 г., 21:34 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 21:23 ч. UTC

Печалби

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2.02.2026 г., 21:19 ч. UTC

Печалби

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:10 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:08 ч. UTC

Печалби

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2.02.2026 г., 21:07 ч. UTC

Печалби

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Net $608.7M >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Rev $1.41B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Adj EPS 25c >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q EPS 24c >PLTR

2.02.2026 г., 20:40 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.